Immatics
-
Moderna Puts Up $120M to Start Cancer Drug R&D Alliance With Immatics
Moderna and Immatics aim to see if the combination of their respective technologies can lead to better cancer treatments spanning multiple therapeutic modalities. Milestone payments to immunotherapy developer Immatics could top $1.7 billion.
-
BMS joins off the shelf cancer therapy chase with Immatics’ T cell-engaging drug
Bristol Myers Squibb is paying $150 million up front for global rights to an Immatics biologic drug designed to recruit a patient’s T cells to go after cancer cells. It’s the latest deal in the field of cancer drug developers aiming for off-the-shelf treatments intended to be easier and less expensive to manufacture, distribute, and administer compared to earlier cell therapies.
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
Celgene invests $75M in cell therapy company Immatics as part of T-cell receptor partnership
Celgene will have opt-in rights to take responsibility for development, manufacturing and commercialization of T-cell receptor therapies that Immatics develops using its in-house technology.